Researchers have identified a type of pro-fibrotic immune cell associated with pulmonary fibrosis (PF) in people who develop persistent breathing problems after recovering from COVID-19. The cells’ abundance correlated with the severity of fibrosis, or tissue scarring, as detected by CT scans. “The underlying cells and molecules that contribute…
News
Insilico Medicine’s ISM001-055 was generally safe and improved lung function in people with idiopathic pulmonary fibrosis (IPF), according to top-line data from a Phase 2a trial. The trial (NCT05938920) enrolled 71 patients with IPF across 21 sites in China who were randomly assigned to receive one of…
A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.
A University of Colorado professor has won the 2024 Alton Ochsner Award Relating Smoking and Disease for his work into how genetic and environmental factors, including smoking, contribute to a person’s risk of idiopathic pulmonary fibrosis (IPF) — when the disease is due to unknown causes. The $15,000 prize…
Avalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF). The MIST trial (NCT06329401) is expected to enroll 300 progressive PF patients, who will receive either one of…
Researchers have identified immune cell populations that could be used to help distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis (IPF), a study suggests. People with hypersensitivity pneumonitis, which is a rare type of pulmonary fibrosis (PF), show elevated levels of certain types of immune cells in the…
This September, supporters will participate in advocacy, educational, and fundraising activities intended to raise awareness about pulmonary fibrosis (PF) and interstitial lung diseases (ILDs) in honor of PF Awareness Month. As it does each year, the Pulmonary Fibrosis Foundation (PFF) will play a central role in the…
Avalyn Pharma has initiated a Phase 1b clinical trial to test AP02, a therapeutic candidate for pulmonary fibrosis (PF), in adult healthy volunteers. The placebo-controlled trial of inhaled nintedanib will assess its safety, tolerability, and pharmacological profile when given at single or multiple ascending doses. Its main goal…
Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating people with pulmonary fibrosis. The patent, No. 12053477, granted by the U.S. Patent and Trademark Office specifically covers the use of brilaroxazine in idiopathic pulmonary fibrosis (IPF), as well…
Brainomix, a U.K.-based software company, has joined forces with Boehringer Ingelheim, a German pharmaceutical company, to accelerate the diagnosis of pulmonary fibrosis (PF) in the U.S. and improve treatment access for people with scarring of the lungs. As part of the collaboration, Brainomix’s artificial intelligence (AI)-powered tool, called Brainomix 360…
